Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
Carlos Doti, VP US Medical Affairs of Oncology at AstraZeneca, shared a post on LinkedIn:
“ASH25 showcased AstraZeneca’s continued growth in hematology.
A decade ago, we presented one abstract. In 2025, we presented 65 abstracts, including:
- 15 oral presentations
- spanning 8 medicines
- 11 diseases
What makes this milestone meaningful isn’t just the science, but how our focus has evolved.
Our responsibility is clear: to help patients have the best quality of life.
As I hear directly from patients, what they want most is freedom from continuous treatment and the chance to return to what truly matters.
Thank you to Mary Caffrey for the opportunity to share these insights and discuss how AstraZeneca is advancing the future of blood cancer care. I encourage you to read the full piece in AJMC – The American Journal of Managed Care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 22, 2026, 13:24Philippa Hill: Blood Clot Awareness – Recognize the Signs, Prevent the Risk
-
Aug 22, 2026, 13:21Chokri Ben Lamine: ASH 2026 Adult Primary ITP Guidelines – Practice-Changing Update
-
Aug 22, 2026, 13:07Saneha Anjum Shaikh: Blood Bank Basics and Quality Control in Automation
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?